DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Morgan Stanley Maintains Overweight on Sage Therapeutics, Lowers Price Target to $117

Morgan Stanley maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $125 to $117.

Benzinga · 03/03/2020 13:18

Morgan Stanley maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $125 to $117.